Q2 2025 Esperion Therapeutics Inc Earnings Call Transcript
Key Points
- Esperion Therapeutics Inc (ESPR) reported a standout second quarter with double-digit sequential growth and more than 42% year-over-year gains in US net product sales.
- The company achieved its first quarter of operating income from ongoing business, reflecting strong commercial execution and payer alignment.
- Esperion's marketing initiatives, including the 'Can't take a statin? Make NEXLIZET happen' campaign, have significantly increased brand awareness and engagement.
- The company has expanded its prescriber base to over 28,000 healthcare practitioners, with a 10% increase in total retail prescription equivalents from the first quarter of 2025.
- Esperion's international partnerships are progressing well, with significant milestones expected, including up to $120 million in milestone payments from the Japanese market.
- Collaboration revenue decreased by approximately 7% compared to the same period in 2024, driven by a prior settlement agreement milestone.
- Research and development expenses decreased by 37%, which may indicate a slowdown in new product development or innovation.
- Selling, general, and administrative expenses decreased by 11%, primarily due to reduced media and marketing costs, which could impact future brand visibility.
- Esperion has not provided specific guidance on script growth or revenue targets, which may create uncertainty for investors.
- The company faces potential competition from new oral non-statin LDL-lowering agents entering the market, which could impact its market share.
Hello, ladies and gentlemen, and thank you for standing by, and welcome to Esperion's second quarter 2025 financial results. (Operator Instructions) Please be advised that today's conference is being recorded.
I would now like to hand the conference over to Alina Venezia, Head of Investor Relations for Esperion Therapeutics. Please go ahead.
Thank you, operator. Good morning, and welcome to Esperion's Second Quarter 2025 Earnings Conference Call. With us on today's call are Sheldon Koenig, President and CEO; and Ben Halladay, CFO. Other members of the Executive team will be available for Q&A following our prepared remarks. We issued a press release earlier this morning detailing the content of today's call.
A copy can be found on the Investor page of our website together with a copy of the presentation that we will also be referencing. I want to remind callers that the information discussed on today's call is covered under the safe harbor provisions of the Private
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
